A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

• Status: Not yet recruiting
• Trial end date: 2027-12-31

Summary

This study will use a combination of Brentuximab vedotin with CHP to treat adult Chinese participants with CD30+ PTCL.

The main aims of the study are to evaluate:

• Side effect from the A+CHP

• Check how much A+CHP stays in their blood over time. This will help Takeda to work out the best dose to give people in the future.

• If A+CHP improves outcome of newly diagnosed CD30+ PTCL

Brentuximab vedotin will be given through vein on Day 1 of each 21-day cycle. Cyclophosphamide and doxorubicin will be given through vein. Prednisone will be given orally daily on Days 1 through 5.

• Phase: Phase 2

Details

• Lead Sponsor: Takeda
• Treatments: Brentuximab Vedotin; Cyclophosphamide; Doxorubicin; Prednisone